Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16941095 | 0.85 | CTSK (0.39) | CTSKCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3711368 | 0.84 | CTSK (0.38) | CTSKCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25113381 | 0.82 | CTSK (0.38) | CTSKCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21610069 | 0.82 | CTSK (0.38) | CTSKCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2917271 | 0.82 | HDAC6 (0.39) | CTSKCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18431705 | 0.82 | CTSK (0.38) | CTSKCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14547678 | 0.82 | CTSK (0.38) | CTSKCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22766361 | 0.81 | HDAC6 (0.34) | CTSKHDAC6CA14HDAC1HDAC2 | |
| SCHEMBL21574215 | 0.81 | CTSK (0.40) | CTSKCHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19646813 | 0.81 | CHRNB2 (0.38) | CTSKCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230233546-A1 | METHODS OF TREATING CANCER | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-2391603-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233546-A1 | METHODS OF TREATING CANCER | TP53, MDM2, MCL1 | CTSK 358/4885CHRNB2 4813/4885CHRNA4 4840/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | CTSK 732/4885CHRNB2 4571/4885CHRNA4 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.